HTB

Lipodystrophy and metabolic complications

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy

Intestinal microflora and low grade metabolic inflammation

Complex connections between bone and fat metabolism

UK studies on bone health: increasedfracture rates reported in HIV-positive people

12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-–6 November 2010, London

Bio-Alcamid associated with unacceptablecomplication risk: no longer recommended as a treatment for facial lipoatrophy

Age raises fracture risk more in HIV-positive people

FDA approves tesamorelin for reduction of central fat accumulation

Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US

75% HIV-positive children have insufficient levels of Vitamin D

High rates of osteopenia and osteoporosis: importance of DEXA monitoring

ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients

Clinical benefits of stopping smoking: CVD and CHD risk returns to that of ‘previous smoker’ in HIV-positive people within three years

Vitamin D deficiencies in HIV management

Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men

Gender and race differences in lipodystrophy symptoms

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

Raltegravir body composition study: 48-week DEXA results

Lipid and metabolic changes with ARV combinations

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

Statin use in HIV-positive patients

New-fill used to treat lipoatropy in feet

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

Growth hormone release factor (TH9507) reduces central fat adiposity

d4T associated with significantly increased risk of type-2 diabetes mellitus

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

The role of the metabolic syndrome in HIV

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

Interventions for the management of lipodystrophy and metabolic complications

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

Omega-3 supplement effective to reduce triglycerides

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

rHGH reduces central fat accumulation in adolescent lipodystrophy

Pravastatin improves lipid profiles but not endothelial function

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

Restorative treatments for HIV-associated lipoatrophy

Vancouver researchers urge caution with combinations of lipid drugs

Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company

Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir

Diabetes and HIV and HCV; aging/HIV and diabetes

FDA panel recommends approval of New-Fill

Lipodystrophy regresses in three patients switched to atazanavir

Low-dose rHGH maintains reductions in abdominal fat for 60 weeks

Rosiglitazone shows no benefit for lipoatrophy

Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins

Human histology and persistence of various injectable filler substances for soft tissue augmentation

Lower doses of d4T produce similar efficacy and reduced side effects

Polylactic acid (New-Fill) repairs facial wasting and improves quality of life

Canadian study shows increased interventional cardiovascular procedures associated with HAART

New guidelines for the evaluation and management of dyslipidaemia in HIV patients on HAART (2003)

Treatments for lipoatrophy. Are there improvements? Are they noticeable?

Rosiglitazone significantly increases triglyceride and cholesterol levels and does not improve HAART-associated lipoatrophy

US approves and Europe rejects Serostim (recombinant growth hormone) for treatment of HIV-related wasting

5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris

Underlying mechanisms: adipocytes and cytokines

Post navigation